{"id":"NCT02079246","sponsor":"H. Lundbeck A/S","briefTitle":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","officialTitle":"An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-07","primaryCompletion":"2017-07-06","completion":"2017-07-06","firstPosted":"2014-03-05","resultsPosted":"2018-08-10","lastUpdate":"2018-08-10"},"enrollment":1463,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Idalopirdine 60 mg","otherNames":[]}],"arms":[{"label":"Idalopirdine (Lu AE58054) 60 mg","type":"EXPERIMENTAL"},{"label":"Idalopirdine 60 mg + memantine","type":"EXPERIMENTAL"}],"summary":"To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).","primaryOutcome":{"measure":"Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX","timeFrame":"Baseline II (start of OLEX, week 0) to end of OLEX (week 28)","effectByArm":[{"arm":"Idalopirdine 60 mg","deltaMin":2130,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":258,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","Chile","Croatia","Czechia","Denmark","Estonia","Finland","France","Germany","Hungary","Israel","Italy","Lithuania","Poland","Portugal","Romania","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":1462},"commonTop":["Accidental overdose","Fall"]}}